Related Experiment Video
Updated: Nov 29, 2025

A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
A Multicenter Study of Neutrophil-to-Lymphocyte Ratio in Primary Aldosteronism
Renata Libianto1,2,3, Jinbo Hu4, Min R Chee3
1Centre for Endocrinology and Metabolism, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
Insights
The neutrophil-to-lymphocyte ratio (NLR) does not differentiate primary aldosteronism (PA) from hypertension but indicates PA severity. Higher NLR correlates with aldosterone levels and predicts chronic kidney disease in PA patients.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Primary aldosteronism (PA) patients face higher cardiovascular risks than essential hypertension patients.
- Excessive aldosterone in PA drives inflammation and mineralocorticoid receptor activation, contributing to cardiovascular damage.
- Neutrophil-to-lymphocyte ratio (NLR) is an accessible inflammation marker linked to cardiovascular outcomes.
Purpose of the Study:
- To investigate the utility of NLR as a biomarker for identifying PA.
- To assess NLR's role in reflecting PA severity and associated comorbidities.
Main Methods:
- Retrospective analysis of NLR from 355 PA patients and 222 hypertensive controls from Australian and Chinese databases.
- NLR data collected from routine blood tests before PA treatment initiation.
Main Results:
- NLR did not significantly differ between PA patients and controls (median 2.3 vs. 2.4, P=0.563).
- In PA patients, NLR positively correlated with aldosterone levels (r=0.22, P<0.001) and negatively with serum potassium (r=-0.15, P=0.006).
- NLR predicted chronic kidney disease (CKD) in PA patients (OR=1.5, P=0.003).
Conclusions:
- NLR is not a diagnostic marker for PA but reflects disease severity.
- NLR is associated with aldosterone concentration and predicts the presence of CKD in PA patients.
- Further prospective studies are warranted to explore NLR's role in predicting PA-related end-organ damage.
Background:
Hypertensive patients with primary aldosteronism (PA) have a higher risk of cardiovascular complications than those with blood pressure-matched essential hypertension. The excess cardiovascular consequences of PA can be attributed to the proinflammatory effect of excessive aldosterone and mineralocorticoid receptor activation in a range of peripheral tissues and cell types. The neutrophil-to-lymphocyte ratio (NLR) is a widely available marker of inflammation which has been shown to predict cardiovascular outcome in the general population. This study aims to evaluate the use of NLR as a potential biomarker of PA and PA severity.
Methods:
Patients with PA (n = 355) were identified from 2 large PA databases in Australia and China, while controls (n = 222) were patients with hypertension who were referred for assessment but did not meet the diagnostic criteria for PA. The NLR was retrospectively collected from routine full blood examination, prior to commencement of targeted treatment for PA.
Results:
The NLR did not differ between PA patients and hypertensive controls (median 2.3 and 2.4, P = 0.563). However, among patients with PA, the NLR was positively correlated with baseline and post-saline aldosterone levels (r = 0.22 and P < 0.001 for both) and negatively correlated with serum potassium (r = -0.15, P = 0.006). Furthermore, in a logistic regression analysis of data from patients with PA, the NLR predicted the presence of comorbid chronic kidney disease (CKD) (defined as estimated glomerular filtration rate <60 mL/min/1.73m2) with an odds ratio of 1.5 (P = 0.003).
Conclusion:
While the NLR did not distinguish PA from controls, it was a marker of PA severity, being associated with aldosterone concentration as well as the presence of CKD. A prospective study is needed to further clarify the role of NLR in predicting end-organ damage associated with PA.
More Related Videos
14:04Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016